Hints and tips:
...To be fair, many have escaped to the seaside towns outside of New York City since the widespread coronavirus lockdowns in March, but few are getting R&R at the moment....
...“We want to add to our pipeline organically through our own R&D and through acquisitions,” he said, adding that the proceeds would not go to paying down debt....
...AstraZeneca Plc has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal...
...Allergan has a strong long-term outlook across its four key therapeutics areas and a highly promising R&D pipeline.”...
...H & R Block, meanwhile, was the biggest decliner on the benchmark index, tumbling nearly 19 per cent to $24.04 after issuing disappointing margin guidance....
...The swift unravelling of the toy seller, at $6.9bn the third-largest retail bankruptcy in history, jolted vendors, who are critical to a retailer’s health....
...In July, DWCP sold a portfolio worth more than $9.4bn to Guangzhou-based developer R&F as well as acquisitive property developer Sunac....
...But now the humble pakora — and its makers — have emerged at the heart of a passionate debate about India’s economic health....
...Health....
...Company earnings and updates for Thursday include Next, WM Morrison, Four Seasons Health, Indigo Vision, MS Amlin, Ophir Energy and Spire Healthcare....
...Critics have accused GSK of turning away from R&D after its $20bn asset swap with Novartis deepened the company’s diversification into vaccines and consumer health....
...This has left the company’s share price almost unchanged over the period while the S&P pharmaceuticals index has doubled....
...Downward pricing pressure hitherto associated with the cash-strapped public health systems of Europe has been spreading across the Atlantic, as the US gets serious about cutting waste from its private health...
...But they are joined by well-known US companies such as Weight Watchers, Toys R Us, Sears, and Advanced Micro Devices, a chipmaker....
...Groups from Macy’s to Urban Outfitters have reported falling revenues and missed analysts’ estimates in recent days, pushing the S&P Retail Select Industry Index down 8.5 per cent last week to mark the sector...
...This optimism is reflected in the 40 per cent jump in the S&P pharmaceuticals index over the past year, compared with a 7 per cent rise in the broader S&P 500....
...Over the past five years CSL has invested US$2bn in R&D and employs more than 1,000 scientists....
...Known as an “immunotherapy”, it was one of the first treatments of its kind to win approval from US health regulators....
...The IPO will fund R&D, marketing and “opportunistic” acquisitions....
...The S&P 500 energy index fell 0.8 per cent to 590.83 while the small-cap S&P 600 energy index rose 0.4 per cent to 1,085.57....
...A dozen of its S&P 500 peers have climbed more than 40 per cent....
...Meanwhile, the company’s R&D as a percentage of sales, which has been falling since 2001, is creeping ever lower....
...Among the 10 biggest biotech companies, average annual sales and earnings growth is more than three times that of the S&P 500 average....
...can curb moral hazard (Financial Times, Kay) Why Valeant’s R&D cuts are under scrutiny (WSJ) The Brazilian World Cup has exposed growing public antipathy fuelled by spiralling costs, police action and...
...Cardinal Health shares suffered, dropping 8.2 per cent to $42.35 after the pharmaceutical company said its contract with Walgreens to distribute its products would not be renewed after expiring on August...
International Edition